Please wait while the formulary information is being retrieved.
Drug overview for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
Generic name: neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone (nee-oh-MY-sin/ba-sih-TRAY-sin/paw-lee-MIX-in/hi-dro-KOR-tih-sown)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Bacitracin is a polypeptide antibiotic. Hydrocortisone is a corticosteroid secreted by the adrenal cortex. Neomycin is an aminoglycoside antibiotic. Polymyxin B is a polymyxin antibiotic.
No enhanced Uses information available for this drug.
Generic name: neomycin sulfate/bacitracin zinc/polymyxin B/hydrocortisone (nee-oh-MY-sin/ba-sih-TRAY-sin/paw-lee-MIX-in/hi-dro-KOR-tih-sown)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Bacitracin is a polypeptide antibiotic. Hydrocortisone is a corticosteroid secreted by the adrenal cortex. Neomycin is an aminoglycoside antibiotic. Polymyxin B is a polymyxin antibiotic.
No enhanced Uses information available for this drug.
DRUG IMAGES
- NEO-POLYCIN HC EYE OINTMENT
The following indications for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone) have been approved by the FDA:
Indications:
Bacterial blepharitis
Bacterial keratitis
Blepharoconjunctivitis
Corneal abrasion
Keratitis
Professional Synonyms:
Corneal abrasion injury
Corneal injury
Indications:
Bacterial blepharitis
Bacterial keratitis
Blepharoconjunctivitis
Corneal abrasion
Keratitis
Professional Synonyms:
Corneal abrasion injury
Corneal injury
The following dosing information is available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
Hydrocortisone or its acetate ester is applied topically to the eye or ear. For ophthalmic or otic use, hydrocortisone and hydrocortisone acetate currently are commercially available only in fixed-combination preparations.
Care should be taken to avoid contamination of the tip of the ointment tube or dropper of the solution or suspension when the drug is used ophthalmically.
Dosage of bacitracin or bacitracin zinc is expressed in terms of the base.
Dosage of neomycin sulfate is expressed in terms of the base.
Potency and dosage of polymyxin B sulfate are expressed in terms of polymyxin B activity (units of polymyxin B).
Care should be taken to avoid contamination of the tip of the ointment tube or dropper of the solution or suspension when the drug is used ophthalmically.
Dosage of bacitracin or bacitracin zinc is expressed in terms of the base.
Dosage of neomycin sulfate is expressed in terms of the base.
Potency and dosage of polymyxin B sulfate are expressed in terms of polymyxin B activity (units of polymyxin B).
No enhanced Administration information available for this drug.
DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
---|---|---|
NEO-POLYCIN HC EYE OINTMENT | Maintenance | Adults apply a small amount into the conjunctival sac(s) in affected eye(s) by ophthalmic route every 4 hours |
DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
---|---|---|
NEO-BACIT-POLY-HC EYE OINTMENT | Maintenance | Adults apply a small amount into the conjunctival sac(s) in affected eye(s) by ophthalmic route every 4 hours |
The following drug interaction information is available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 4 contraindications.
Absolute contraindication.
Contraindication List |
---|
Fungal infection of eye |
Herpes simplex dendritic keratitis |
Tuberculosis of the eye |
Vaccinia virus keratitis |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
Severe List |
---|
Amebic infection of the eye |
Ocular hypertension |
Ocular injury |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
Moderate List |
---|
Diabetes mellitus |
Krukenberg spindle |
No disease contraindications |
Open angle glaucoma |
Severe myopia |
The following adverse reaction information is available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 28 severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Contact dermatitis Ocular inflammation Ocular itching Ocular redness Skin rash |
Ocular hypertension Ocular irritation |
Rare/Very Rare |
---|
Adrenocortical insufficiency Anaphylaxis Bullous dermatitis Cataracts Central serous chorioretinopathy Corneal degeneration Corneal edema Corneal erosion Corneal ulcer Fungal infection of eye Glaucoma Globe perforation Hypercortisolism Hypersensitivity drug reaction Keratitis Optic nerve damage Punctate keratitis Reduced visual acuity Uveitis Visual changes Visual field defect |
There are 25 less severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Blurred vision |
Blurred vision Headache disorder Iritis Ocular irritation Ocular pain |
Rare/Very Rare |
---|
Accommodation disorder Allergic dermatitis Blepharoptosis Calcification of cornea Chemosis Conjunctival hyperemia Conjunctivitis Dizziness Dysgeusia Eye tearing Foreign body sensation of eye Impaired wound healing Mydriasis Ocular infection Ocular irritation Ocular itching Ocular redness Photophobia Urticaria |
The following precautions are available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
None |
Severe Precaution
None |
Management or Monitoring Precaution
None |
Animal reproduction studies have not been performed with bacitracin. It is not known whether ophthalmic preparations containing bacitracin or bacitracin zinc can cause fetal harm when administered to pregnant women. Fixed-combination ophthalmic preparations containing bacitracin zinc and polymyxin B sulfate with or without neomycin sulfate should be used during pregnancy only if clearly needed.
Fixed-combination ophthalmic preparations containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and a corticosteroid (i.e., hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Animal reproduction studies have not been conducted with neomycin sulfate. It is not known whether ophthalmic or otic preparations containing neomycin sulfate can cause fetal harm when administered to a pregnant woman.
Fixed-combination ophthalmic preparations containing neomycin sulfate, polymyxin B sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed. Fixed-combination ophthalmic preparations containing neomycin sulfate, other anti-infectives (i.e., polymyxin B sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing neomycin sulfate, colistin, and hydrocortisone acetate should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Although aminoglycosides can cause congenital deafness in humans if administered during pregnancy, the manufacturers state that clinically important systemic concentrations of neomycin are not anticipated when otic preparations containing neomycin are used as directed. Fixed-combination otic preparations containing neomycin sulfate, polymyxin B sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus. Animal reproduction studies have not been performed with polymyxin B sulfate.
It is not known whether ophthalmic preparations containing polymyxin B sulfate can cause fetal harm when administered to pregnant women. Fixed-combination ophthalmic preparations of polymyxin B sulfate and bacitracin zinc or polymyxin B sulfate, neomycin sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed. Because trimethoprim may interfere with folic acid metabolism, fixed-combination ophthalmic preparations containing polymyxin B sulfate and trimethoprim sulfate should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Fixed-combination ophthalmic preparations containing polymyxin B sulfate, other anti-infectives (i.e., neomycin sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Fixed-combination ophthalmic preparations containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and a corticosteroid (i.e., hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Animal reproduction studies have not been conducted with neomycin sulfate. It is not known whether ophthalmic or otic preparations containing neomycin sulfate can cause fetal harm when administered to a pregnant woman.
Fixed-combination ophthalmic preparations containing neomycin sulfate, polymyxin B sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed. Fixed-combination ophthalmic preparations containing neomycin sulfate, other anti-infectives (i.e., polymyxin B sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing neomycin sulfate, colistin, and hydrocortisone acetate should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Although aminoglycosides can cause congenital deafness in humans if administered during pregnancy, the manufacturers state that clinically important systemic concentrations of neomycin are not anticipated when otic preparations containing neomycin are used as directed. Fixed-combination otic preparations containing neomycin sulfate, polymyxin B sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus. Animal reproduction studies have not been performed with polymyxin B sulfate.
It is not known whether ophthalmic preparations containing polymyxin B sulfate can cause fetal harm when administered to pregnant women. Fixed-combination ophthalmic preparations of polymyxin B sulfate and bacitracin zinc or polymyxin B sulfate, neomycin sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed. Because trimethoprim may interfere with folic acid metabolism, fixed-combination ophthalmic preparations containing polymyxin B sulfate and trimethoprim sulfate should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Fixed-combination ophthalmic preparations containing polymyxin B sulfate, other anti-infectives (i.e., neomycin sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus.
It is not know whether bacitracin is distributed into milk. Bacitracin and fixed-combination ophthalmic preparations containing bacitracin zinc and polymyxin B sulfate with or without neomycin sulfate should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and a corticosteroid (i.e., hydrocortisone, hydrocortisone acetate) state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman.
Some experts consider topical bacitracin compatible with nursing. It is not known whether neomycin is distributed into milk. Fixed-combination ophthalmic preparations containing neomycin sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, polymyxin B sulfate) should be used with caution in nursing women.
Fixed-combination ophthalmic preparations containing neomycin sulfate, polymyxin B sulfate, and dexamethasone should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing neomycin sulfate, polymyxin B sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing neomycin sulfate, colistin, and hydrocortisone acetate and fixed-combination otic preparations containing neomycin sulfate, polymyxin B sulfate, and hydrocortisone should be used with caution in nursing women.
Fixed-combination ophthalmic preparations containing polymyxin B sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, neomycin sulfate, trimethoprim sulfate) should be used with caution in nursing women. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, and dexamethasone should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used with caution in nursing women.
Some experts consider topical bacitracin compatible with nursing. It is not known whether neomycin is distributed into milk. Fixed-combination ophthalmic preparations containing neomycin sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, polymyxin B sulfate) should be used with caution in nursing women.
Fixed-combination ophthalmic preparations containing neomycin sulfate, polymyxin B sulfate, and dexamethasone should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing neomycin sulfate, polymyxin B sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing neomycin sulfate, colistin, and hydrocortisone acetate and fixed-combination otic preparations containing neomycin sulfate, polymyxin B sulfate, and hydrocortisone should be used with caution in nursing women.
Fixed-combination ophthalmic preparations containing polymyxin B sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, neomycin sulfate, trimethoprim sulfate) should be used with caution in nursing women. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, and dexamethasone should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for NEO-POLYCIN HC (neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone)'s list of indications:
Bacterial blepharitis | |
H01.0 | Blepharitis |
H01.00 | Unspecified blepharitis |
H01.001 | Unspecified blepharitis right upper eyelid |
H01.002 | Unspecified blepharitis right lower eyelid |
H01.003 | Unspecified blepharitis right eye, unspecified eyelid |
H01.004 | Unspecified blepharitis left upper eyelid |
H01.005 | Unspecified blepharitis left lower eyelid |
H01.006 | Unspecified blepharitis left eye, unspecified eyelid |
H01.009 | Unspecified blepharitis unspecified eye, unspecified eyelid |
H01.00A | Unspecified blepharitis right eye, upper and lower eyelids |
H01.00B | Unspecified blepharitis left eye, upper and lower eyelids |
H01.01 | Ulcerative blepharitis |
H01.011 | Ulcerative blepharitis right upper eyelid |
H01.012 | Ulcerative blepharitis right lower eyelid |
H01.013 | Ulcerative blepharitis right eye, unspecified eyelid |
H01.014 | Ulcerative blepharitis left upper eyelid |
H01.015 | Ulcerative blepharitis left lower eyelid |
H01.016 | Ulcerative blepharitis left eye, unspecified eyelid |
H01.019 | Ulcerative blepharitis unspecified eye, unspecified eyelid |
H01.01A | Ulcerative blepharitis right eye, upper and lower eyelids |
H01.01B | Ulcerative blepharitis left eye, upper and lower eyelids |
H01.02 | Squamous blepharitis |
H01.021 | Squamous blepharitis right upper eyelid |
H01.022 | Squamous blepharitis right lower eyelid |
H01.023 | Squamous blepharitis right eye, unspecified eyelid |
H01.024 | Squamous blepharitis left upper eyelid |
H01.025 | Squamous blepharitis left lower eyelid |
H01.026 | Squamous blepharitis left eye, unspecified eyelid |
H01.029 | Squamous blepharitis unspecified eye, unspecified eyelid |
H01.02A | Squamous blepharitis right eye, upper and lower eyelids |
H01.02B | Squamous blepharitis left eye, upper and lower eyelids |
Bacterial keratitis | |
H16.10 | Unspecified superficial keratitis |
H16.101 | Unspecified superficial keratitis, right eye |
H16.102 | Unspecified superficial keratitis, left eye |
H16.103 | Unspecified superficial keratitis, bilateral |
H16.109 | Unspecified superficial keratitis, unspecified eye |
H16.32 | Diffuse interstitial keratitis |
H16.321 | Diffuse interstitial keratitis, right eye |
H16.322 | Diffuse interstitial keratitis, left eye |
H16.323 | Diffuse interstitial keratitis, bilateral |
H16.329 | Diffuse interstitial keratitis, unspecified eye |
H16.39 | Other interstitial and deep keratitis |
H16.391 | Other interstitial and deep keratitis, right eye |
H16.392 | Other interstitial and deep keratitis, left eye |
H16.393 | Other interstitial and deep keratitis, bilateral |
H16.399 | Other interstitial and deep keratitis, unspecified eye |
H16.8 | Other keratitis |
Blepharoconjunctivitis | |
H10.5 | Blepharoconjunctivitis |
H10.50 | Unspecified blepharoconjunctivitis |
H10.501 | Unspecified blepharoconjunctivitis, right eye |
H10.502 | Unspecified blepharoconjunctivitis, left eye |
H10.503 | Unspecified blepharoconjunctivitis, bilateral |
H10.509 | Unspecified blepharoconjunctivitis, unspecified eye |
H10.52 | Angular blepharoconjunctivitis |
H10.521 | Angular blepharoconjunctivitis, right eye |
H10.522 | Angular blepharoconjunctivitis, left eye |
H10.523 | Angular blepharoconjunctivitis, bilateral |
H10.529 | Angular blepharoconjunctivitis, unspecified eye |
Corneal abrasion | |
S05.00xA | Injury of conjunctiva and corneal abrasion without foreign body, unspecified eye, initial encounter |
S05.01xA | Injury of conjunctiva and corneal abrasion without foreign body, right eye, initial encounter |
S05.02xA | Injury of conjunctiva and corneal abrasion without foreign body, left eye, initial encounter |
Keratitis | |
H16 | Keratitis |
H16.10 | Unspecified superficial keratitis |
H16.101 | Unspecified superficial keratitis, right eye |
H16.102 | Unspecified superficial keratitis, left eye |
H16.103 | Unspecified superficial keratitis, bilateral |
H16.109 | Unspecified superficial keratitis, unspecified eye |
H16.11 | Macular keratitis |
H16.111 | Macular keratitis, right eye |
H16.112 | Macular keratitis, left eye |
H16.113 | Macular keratitis, bilateral |
H16.119 | Macular keratitis, unspecified eye |
H16.12 | Filamentary keratitis |
H16.121 | Filamentary keratitis, right eye |
H16.122 | Filamentary keratitis, left eye |
H16.123 | Filamentary keratitis, bilateral |
H16.129 | Filamentary keratitis, unspecified eye |
H16.13 | Photokeratitis |
H16.131 | Photokeratitis, right eye |
H16.132 | Photokeratitis, left eye |
H16.133 | Photokeratitis, bilateral |
H16.139 | Photokeratitis, unspecified eye |
H16.14 | Punctate keratitis |
H16.141 | Punctate keratitis, right eye |
H16.142 | Punctate keratitis, left eye |
H16.143 | Punctate keratitis, bilateral |
H16.149 | Punctate keratitis, unspecified eye |
H16.30 | Unspecified interstitial keratitis |
H16.301 | Unspecified interstitial keratitis, right eye |
H16.302 | Unspecified interstitial keratitis, left eye |
H16.303 | Unspecified interstitial keratitis, bilateral |
H16.309 | Unspecified interstitial keratitis, unspecified eye |
H16.32 | Diffuse interstitial keratitis |
H16.321 | Diffuse interstitial keratitis, right eye |
H16.322 | Diffuse interstitial keratitis, left eye |
H16.323 | Diffuse interstitial keratitis, bilateral |
H16.329 | Diffuse interstitial keratitis, unspecified eye |
H16.33 | Sclerosing keratitis |
H16.331 | Sclerosing keratitis, right eye |
H16.332 | Sclerosing keratitis, left eye |
H16.333 | Sclerosing keratitis, bilateral |
H16.339 | Sclerosing keratitis, unspecified eye |
H16.39 | Other interstitial and deep keratitis |
H16.391 | Other interstitial and deep keratitis, right eye |
H16.392 | Other interstitial and deep keratitis, left eye |
H16.393 | Other interstitial and deep keratitis, bilateral |
H16.399 | Other interstitial and deep keratitis, unspecified eye |
H16.8 | Other keratitis |
H16.9 | Unspecified keratitis |
Formulary Reference Tool